Literature and evidence database
Find the source, the model and the boundary.
Search source records connected to the product-family knowledge base. Filter by category, product, publication year, research type, study model and editorial evidence tier.
Product evidence maps
A focused source set for each product.
Search and filter
Evidence records
Narrow the records by product, year or study model. Open each source to check its results and limitations.
Performance-enhancing peptides modulating the GH-IGF1 axis
Critical review. 2026. PMID 42395176.
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats
Biçer O, et al. Jt Dis Relat Surg. 2026;37:822–837. PMID 42542926.
Survodutide Once Weekly for the Treatment of Adults with Obesity
le Roux CW, et al. New England Journal of Medicine. 2026. PMID 42253238 · DOI 10.1056/NEJMoa2600751.
FDA concerns with unapproved GLP-1 drugs used for weight loss
U.S. Food and Drug Administration. Content current through May 31, 2026.
TRIUMPH-1 sponsor-reported topline results
Eli Lilly and Company. May 21, 2026. Sponsor news release; not a full peer-reviewed report.
TRIUMPH-2 and TRIUMPH-3 sponsor-reported topline results
Eli Lilly and Company. July 23, 2026. Sponsor news release; detailed publication pending.
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Evidence review. 2026. PMID 41476424.
PubChem Compound Summary for CID 950107: 5-Amino-1-methylquinolinium
National Center for Biotechnology Information. PubChem CID 950107; record modified July 25, 2026.
Gonadotropin strategies in congenital hypogonadotropic hypogonadism
2026 open-label randomized study of 45 men; PMID 41993983.
FOXO4-DRI and endothelial-cell senescence
2026 endothelial and mouse-aging-model study; PMID 41625068.
TGA finds inconsistent Melanotan II content
Official August 2026 laboratory-testing safety alert.
REIMAGINE 2 cagrilintide-semaglutide comparative phase 3 study
2026 comparative trial; PMID 42251859.
ZEPBOUND (tirzepatide) prescribing information
U.S. FDA. Revised 2026. NDA 217806.
What to know about retatrutide
Eli Lilly and Company. Medically reviewed; updated July 2026.
MOUNJARO (tirzepatide) current prescribing information
U.S. Food and Drug Administration. Revised December 2025. Initial U.S. approval 2022.
EGRIFTA WR (tesamorelin) prescribing information
U.S. Food and Drug Administration. 2025 labeling record for BLA 022505.
FDA Drug Trials Snapshot: Forzinity
U.S. FDA. Approval date September 19, 2025; SPIBA-201 population and endpoint record.
Semax targets Oprm1 in a spinal-cord-injury mouse model
Preclinical study. 2025. PMID 40692165.
PNC-27 experimental antitumor study
Preclinical study. 2025. PMID 40750238.
Epitalon and telomere length in human cell lines
Cell study. 2025. PMID 40908429.
Randomized trial involving human menopausal gonadotropin
Clinical trial. 2025. PMID 40193016.
KPV mitigates fine-dust-induced keratinocyte apoptosis and inflammation
Cell study. 2025. PMID 40073467.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
N Engl J Med. 2025. PMID 40544433.
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
N Engl J Med. 2025. PMID 40544432.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine
Systematic review. 2025. PMID 40756949.
Multifunctionality and Possible Medical Application of the BPC 157 Peptide
Literature and patent review. 2025. PMID 40005999.
DailyMed Oxytocin Injection, USP label
Official U.S. prescription label, updated March 2025.
TESTS phase 3 thymosin alpha-1 sepsis trial
Primary 2025 multicenter trial; PMID 39814420.
VIP promotes secretory differentiation and mitigates radiation-induced intestinal injury
Preclinical study. 2024. PMID 39380035.
Thymalin in rat mandibular regeneration
Preclinical study. 2024. PMID 38642352.
Editorial methodology
How records are classified
Records are deduplicated by source URL and linked to every relevant product family. Study type and model are inferred from the citation and editorial evidence label, then reviewed during content QA.
Read the full editorial, AI-assistance and correction policy →
Labels and databases supporting regulatory status, formulation or chemical identity.
Controlled trials, systematic reviews and other clinical records with population-specific interpretation.
Animal, cell, analytical and mechanistic records that cannot establish human outcomes.
Narrative reviews, registries and sponsor reports kept visibly distinct from peer-reviewed outcomes.
Use the records
